Caissa Capital Management ltd. - 12 May 2023 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role
10%+ Owner
Signature
Cambyz Golestaneh, Title: Director
Issuer symbol
AVTX
Transactions as of
12 May 2023
Net transactions value
+$11,007
Form type
4
Filing time
16 May 2023, 17:23:43 UTC
Previous filing
08 May 2023
Next filing
22 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTX Common stock Purchase $5,598 +2,285 +0.17% $2.45 1,344,985 12 May 2023 See Footnote (1) F1
transaction AVTX Common stock Purchase $4,366 +1,715 +0.13% $2.55 1,346,700 15 May 2023 See Footnote (1) F1, F2
transaction AVTX Common stock Purchase $1,042 +379 +0.03% $2.75* 1,347,079 16 May 2023 See Footnote (1) F1
holding AVTX Common stock 182,300 12 May 2023 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh.
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.45 to $2.79, inclusive.
F3 These shares are directly owned by Mr. Golestaneh in his personal capacity.